Skip to main content

News

Research Review
03/18/2026
Jessica Garlewicz
Joint and skin complications remain frequent among IBD patients even after escalation to advanced therapy, underscoring the importance of ongoing surveillance for EIMs.
Joint and skin complications remain frequent among IBD patients even after escalation to advanced therapy, underscoring the importance of ongoing surveillance for EIMs.
Joint and skin complications...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
03/18/2026
Jessica Garlewicz
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
03/18/2026
Jessica Garlewicz
Subcutaneous dosing appears to offer a practical alternative to intravenous induction for IL-23/p19 inhibitors in ulcerative colitis.
Subcutaneous dosing appears to offer a practical alternative to intravenous induction for IL-23/p19 inhibitors in ulcerative colitis.
Subcutaneous dosing appears to...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
03/18/2026
Jessica Garlewicz
Risk stratification and postoperative prophylaxis are important for patients who have undergone segmental colectomy for Crohn’s disease, researchers reported.
Risk stratification and postoperative prophylaxis are important for patients who have undergone segmental colectomy for Crohn’s disease, researchers reported.
Risk stratification and...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
03/18/2026
Jessica Garlewicz
For practicing gastroenterologists, etrasimod offers a durable oral option for UC patients across a spectrum of endoscopic severity, including those with severe mucosal disease, with evidence supporting continued gains during maintenance...
For practicing gastroenterologists, etrasimod offers a durable oral option for UC patients across a spectrum of endoscopic severity, including those with severe mucosal disease, with evidence supporting continued gains during maintenance...
For practicing...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
03/18/2026
Jessica Garlewicz
The findings of a recent claims analysis highlight gaps between risk burden and treatment patterns in real-world practice.
The findings of a recent claims analysis highlight gaps between risk burden and treatment patterns in real-world practice.
The findings of a recent claims...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Review
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Surgery
01/20/2026
Jessica Garlewicz
This research adds to growing interest in the potential immunomodulatory effects of statins beyond cardiovascular risk reduction.
This research adds to growing interest in the potential immunomodulatory effects of statins beyond cardiovascular risk reduction.
This research adds to growing...
01/20/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
01/14/2026
Jessica Garlewicz
Endoscopic response, transmural remission, and transmural response rates showed no significant differences between treatment groups at either assessment window.
Endoscopic response, transmural remission, and transmural response rates showed no significant differences between treatment groups at either assessment window.
Endoscopic response, transmural...
01/14/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
01/14/2026
Jessica Garlewicz
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis...
01/14/2026
Advances in Inflammatory Bowel Disease Network